Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dust mite and Lepidoglyphus destructor allergen immunotherapy trial in allergic rhinitis/rhinoconjunctivitis
2025-522771-28-00Phase 3Authorised
- Sponsor
- Inmunotek
- Start
- Sep 2026
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dermatophagoides pteronyssinus allergoid + dermatophagoides farinae allergoid + lepidoglyphus destructor polymerised extract in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and allergic asthma (2 arms), sponsored by Inmunotek. Primary endpoint: Rhinoconjunctivitis Combined Symptom and Medication Score. Planned start Sep 2026; status: authorised.
02
Drugs
dermatophagoides pteronyssinus allergoid + dermatophagoides farinae allergoid + lepidoglyphus destructor polymerised extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on 2025-522771-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522771-28-00.